Comparative assessment of modern parameters of glycemic control in children with type 1 diabetes after switching to fast-acting insulin aspart using Flash Glucose Monitoring in real clinical practice

BACKGROUND: Postprandial hyperglycaemia contributes significantly to the lack of glycaemic control in patients with type 1 diabetes mellitus (DM1). At least a quarter of patients forget to inject insulin before meals once a week, and more than 40% of them inject bolus insulin immediately before meals, which does not correspond to the pharmacokinetic effects of ultrashort insulins and determines the need to use insulins with better imitations of physiological insulin secretion.

AIM: To assess the effect of fast acting insulin aspart (FIAsp) on the current parameters of glycaemic control in children with DM1 after switching from insulin Asp (iAsp) using continuous glucose monitoring.

MATERIALS AND METHODS: A multicenter observational 12-week prospective open-label uncontrolled comparative study was initiated. A group of insufficiently controlled patients were identified (n = 48) including a group on multiple insulin injections therapy (MII) (insulin degludec and IAsp) and a group on continuous subcutaneous insulin infusion (CSII) of iAsp. Three 14-day flash glucose monitoring (FMG) were performed: before transferring patients to FiAsp and after 2 and 12 weeks of the transfer. Key endpoints: HbA1c after 2 and 12 weeks on FiAsp relative to baseline, analysis of 5 FMG target glucose ranges, presented as an ambulatory glycemic profile. Additional indicators: dynamics of insulin daily dose, frequency of glucose self- monitoring, the number of severe hypoglycemia, adverse events that occurred during treatment.

RESULTS: 2 weeks after the transfer from IAsp to FIAsp, TIR increased in the entire group of patients: from 53% [44.3; 66.5] to 57% [47.4; 71.0] (p-value = 0.010) and TAR decreased from 38% [24.8; 50.2] to 30.5% [22.0; 45, 0] (p-value = 0.0124). Maintaining and increase time spent in the target glucose ranges during a 12-week observation period, in parallel with a significant decrease in hypoglycemic episodes <3.9 mmol / L per week, on FIAsp therapy naturally leads to an improvement in diabetes control: a decrease in HbA1c from 8.15% up to 7.75% (p-value = 0.0224), more pronounced in the group of patients on CSII — from 7.9% to 7.5% (p-value = 0.028).

CONCLUSION: Switching from IAsp to BDIAsp in routine clinical practice in the MII and CSII regimen in children and adolescents with type 1 diabetes allows achieving better glycemic control compared to the previous generation prandial insulin analog Iasp. The better diabetes control is associated with an increase or a trend towards an increase in TIR and a decrease or a trend towards a decrease in TAR and TBR, as well as a significant decrease in episodes of hypoglycemia.

1. Monnier L. Is postprandial glucose a neglected cardiovascular risk factor in type 2 diabetes? Eur J Clin Invest. 2000;30(Suppl 2):3-11. doi: https://doi.org/10.1046/j.1365-2362.30.s2.2.x

2. Woerle HJ, Neumann C, Zschau S, et al. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes. Diabetes Res Clin Pract. 2007;77(2):280-285. doi: https://doi.org/10.1016/j.diabres.2006.11.011

3. Saad A, Dalla Man C, Nandy DK, et al. Diurnal pattern to insulin secretion and insulin action in healthy individuals. Diabetes. 2012;61(11):2691-2700. doi: https://doi.org/10.2337/db11-1478

4. Home PD. Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes? Diabetes Obes Metab. 2015;17(11):1011-1020. doi: https://doi.org/10.1111/dom.12501

5. Overmann H, Heinemann L. Injection-meal interval: recommendations of diabetologists and how patients handle it. Diabetes Res Clin Pract. 1999;43(2):137-142. doi: https://doi.org/10.1016/s0168-8227(98)00132-6

6. Kildegaard J, Buckley ST, Nielsen RH, et al. Elucidating the mechanism of absorption of fast-acting insulin aspart: the role of niacinamide. Pharm Res. 2019;36(3):49. doi: https://doi.org/10.1007/s11095-019-2578-7

7. Biester T, Kordonouri O, Danne T. Pharmacological properties of faster-acting insulin aspart. Curr Diabetes Rep. 2017;17(11):101. doi: https://doi.org/10.1007/s11892-017-0931-y

8. Senior P, Hramiak I. Fast-acting insulin aspart and the need for new mealtime insulin analogues in adults with type 1 and type 2 diabetes: a Canadian perspective. Can J Diabetes. 2019;43(7):515-523. doi: https://doi.org/10.1016/j.jcjd.2019.01.004

9. Pieber TR, Svehlikova E, Brunner M, et al. Fast-acting insulin aspart in subjects with type 2 diabetes: earlier onset and greater initial exposure and glucose-lowering effect compared with insulin aspart. Diabetes Obes Metab. 2019;21(9):2068-2075. doi: https://doi.org/10.1111/dom.13767

10. Heise T, Stender-Petersen K, Hövelmann U, et al. Pharmacokinetic and pharmacodynamic properties of faster-acting insulin aspart versus insulin aspart across a clinically relevant dose range in subjects with type 1 diabetes mellitus. Clin Pharmacokinet. 2017;56(6):649-660. doi: https://doi.org/10.1007/s40262-016-0473-5

11. Basu A, Pieber TR, Hansen AK, et al. Greater early postprandial suppression of endogenous glucose production and higher initial glucose disappearance is achieved with fast-acting insulin aspart compared with insulin aspart. Diabetes Obes Metab. 2018;20(7):1615-1622. doi: https://doi.org/10.1111/dom.13270

12. Fath M, Danne T, Biester T, et al. Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus. Pediatr Diabtes. 2017;18(8):903-910. doi: https://doi.org/10.1111/pedi.12506

13. Shiramoto M, Nishida T, Hansen AK, Haahr H. Fast-acting insulin aspart in Japanese patients with type 1 diabetes: faster onset, higher early exposure and greater early glucose-lowering effect relative to insulin aspart. J Diabetes Investig. 2018;9(2):303-310. doi: https://doi.org/10.1111/jdi.12697

14. Heinemann L, Muchmore DB. Ultrafast-acting insulins: state of the art. J Diabetes Sci Technol. 2012;6(4):728-742. doi: https://doi.org/10.1177/193229681200600402

15. Heise T, Zijlstra E, Nosek L, et al. Pharmacological properties of faster-acting insulin aspart vsinsulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: a randomized, double-blind, crossover trial. J Diabetes Sci Technol. 2018;12(1):145-151. doi: https://doi.org/10.1177/1932296817730375

16. Russell-Jones D, Bode BW, De Block C, et al. Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (onset 1). Diabetes Care. 2017;40(7):943-950. doi: https://doi.org/10.2337/dc16-1771

17. Bode BW, Iotova V, Kovarenko M, et al. Efficacy and safety of fast-acting insulin aspart compared with insulin aspart, both in combination with insulin degludec, in children and adolescents with type 1 diabetes: the onset 7 trial. Diabetes Care. 2019;42(7):1255-1262. doi: https://doi.org/10.2337/dc19-0009

18. Billion L., Charleer S., Verbraeken L., et al. Glucose control using fast-acting insulin aspart in a real-world setting: A 1-year, two-centre study in people with type 1 diabetes using continuous glucose monitoring. Diabetes, Obes Metab. 2021;23(12):2716-2727. doi: https://doi.org/10.1111/dom.14527

19. Danne T, Axel Schweitzer M, Keuthage W, et al. Impact of fast-acting insulin aspart on glycemic control in patients with type 1 diabetes using intermittent-scanning continuous glucose monitoring within a real-world setting: the GoBolus study. Diabetes Technol Ther. 2021;23(3):203-212. doi: https://doi.org/10.1089/dia.2020.0360

20. Mathieu C, Bode BW, Franek E, et al. Efficacy and safety of fast- acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): a 52-week, randomized, treat-to-target, phase III trial. Diabetes Obes Metab. 2018;20(5):1148-1155. doi: https://doi.org/10.1111/dom.13205

21. Bowering K, Case C, Harvey J, et al. Faster aspart versus insulin aspart as part of a basal-bolus regimen in inadequately controlled type 2 diabetes: the onset 2 trial. Diabetes Care. 2017;40(7):951-957. doi: https://doi.org/10.2337/dc16-1770

22. Dovc K, Battelino T. Time in range centered diabetes care. Clin Pediatr Endocrinol. 2021;30(1):1-10. doi: https://doi.org/10.1297/cpe.30.1

23. Bergenstal RM, Ahmann AJ, Bailey T, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP). Diabetes Technol Ther. 2013;15(3):198-211. doi: https://doi.org/10.1089/dia.2013.0051

24. Danne T, Nimri R, Battelino T, et al. International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care. 2017;40(12):1631-1640. doi: https://doi.org/10.2337/dc17-1600

25. World Medical Association declaration of Helsinki. JAMA. 2013;310(20):2191-2194. doi: https://doi.org/10.1001/jama.2013.281053

26. Berger ML, Sox H, Willke RJ, et al. Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making. Pharmacoepidemiol Drug Saf. 2017;26(9):1033-1039. doi: https://doi.org/10.1002/pds.4297

27. Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time in Range. Diabetes Care. 2019;42(8):1593-1603. doi: https://doi.org/10.2337/dci19-0028

28. Ranjan AG, Rosenlund SV, Hansen TW, et al. Improved time in range over 1 year is associated with reduced albuminuria in individuals with sensor-augmented insulin pump–treated type 1 diabetes. Diabetes Care. 2020;43(11):2882-2885. doi: https://doi.org/10.2337/dc20-0909

29. Lee MH, Paldus B, Vogrin S, et al. Fast-Acting Insulin Aspart Versus Insulin Aspart Using a Second-Generation Hybrid Closed-Loop System in Adults With Type 1 Diabetes: A Randomized, Open-Label, Crossover Trial. Diabetes Care. 2021;44(10):2371-2378. doi: https://doi.org/10.2337/dc21-0814